Last but not least, two biomarkers in our panel (Aβ42 and pTau) were selected on the assumption of cortical beta-amyloid and tau as a causal driver for cognitive impairment in MCI/AD; future research should also examine the conceptual basis for cognitive impairment in MCI driven by other factors, such as calcium regulation, metabolism, vascular risks, or inflammatory pathways independent of and/or upstream of beta-amyloid and tau’s effect on cognitive impairment. The gene discussed is MAPT; the disease is Alzheimer disease.